Free Trial
NASDAQ:ENTO

Entero Therapeutics (ENTO) Stock Price, News & Analysis

Entero Therapeutics logo
$0.42 -0.02 (-4.45%)
Closing price 08/1/2025 03:48 PM Eastern
Extended Trading
$0.44 +0.01 (+3.47%)
As of 08/1/2025 07:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Entero Therapeutics Stock (NASDAQ:ENTO)

Key Stats

Today's Range
$0.42
$0.45
50-Day Range
$0.38
$0.59
52-Week Range
$0.19
$0.93
Volume
185,999 shs
Average Volume
1.40 million shs
Market Capitalization
$2.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive ENTO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Entero Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ENTO Stock News Headlines

Entero Therapeutics Inc ENTO
The stealth altcoin the financial world is underestimating
The Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should buy in this market, this token might just be it.
Entero Therapeutics Delays 10-K Filing
Entero Therapeutics names Richard Paolone as interim CEO
See More Headlines

ENTO Stock Analysis - Frequently Asked Questions

Entero Therapeutics' stock was trading at $0.6220 on January 1st, 2025. Since then, ENTO shares have decreased by 32.4% and is now trading at $0.4204.

Entero Therapeutics, Inc. (NASDAQ:ENTO) announced its quarterly earnings results on Thursday, May, 15th. The company reported ($0.21) EPS for the quarter.

Shares of ENTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Entero Therapeutics investors own include Conduit Pharmaceuticals (CDT), BIOLASE (BIOL), Cyclacel Pharmaceuticals (CYCC), Dare Bioscience (DARE), PMGC (ELAB), TRACON Pharmaceuticals (TCON) and Tempest Therapeutics (TPST).

Company Calendar

Last Earnings
5/15/2025
Today
8/02/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ENTO
Previous Symbol
NASDAQ:ENTO
CIK
1604191
Fax
N/A
Employees
9
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$18.06 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-1,063.82%
Return on Assets
-26.06%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.90
Quick Ratio
2.90

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.82) per share
Price / Book
-0.51

Miscellaneous

Outstanding Shares
4,766,000
Free Float
4,730,000
Market Cap
$2.00 million
Optionable
N/A
Beta
0.84
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:ENTO) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners